Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chabner

Showing results (191-200 of 456) with videos related to

Pageof 46
Sort By:
JAMA|May 14, 1997
Screening strategies for cancer. Implications and resultsB A Chabner, F G Haluska, J A Talcott
The Oncologist|July 25, 2013
Clinical trial results: Sharing results, speeding discoveriesAntonio Tito Fojo, Susan E Bates, Bruce A Chabner
The Oncologist|July 2, 2013
Personalized medicine: hype or realityBruce A Chabner, Leif W Ellisen, A John Iafrate
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacodynamic biomarkers: falling short of the mark?Justin F Gainor, Dan L Longo, Bruce A Chabner
Biochemical Pharmacology|April 1, 1986
A re-evaluation of the competitive protein binding assay for methotrexate binding to dihydrofolate reductaseJ C Drake, C J Allegra, B A Chabner
The Oncologist|July 26, 2017
The Harm in KratomJoshua Z Drago, Bennett Lane, Jonathan Kochav, et al.
Targeted Oncology|November 9, 2017
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest DevelopmentsAiko Nagayama, Leif W Ellisen, Bruce Chabner, et al.
The Oncologist|December 1, 2010
New trends and novel treatment for hepatocellular carcinoma: a global perspectiveAndrew X Zhu, Bruce A Chabner, Kenneth K Tanabe
Advances in Enzyme Regulation|January 1, 1989
Future directions for antifolate drug developmentC B Knight, P C Elwood, B A Chabner
The New England Journal of Medicine|March 1, 2013
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Pageof 46

Showing results (191-200 of 456) with videos related to

Sort By:
Pageof 46
JAMA|May 14, 1997
Screening strategies for cancer. Implications and resultsB A Chabner, F G Haluska, J A Talcott
The Oncologist|July 25, 2013
Clinical trial results: Sharing results, speeding discoveriesAntonio Tito Fojo, Susan E Bates, Bruce A Chabner
The Oncologist|July 2, 2013
Personalized medicine: hype or realityBruce A Chabner, Leif W Ellisen, A John Iafrate
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacodynamic biomarkers: falling short of the mark?Justin F Gainor, Dan L Longo, Bruce A Chabner
Biochemical Pharmacology|April 1, 1986
A re-evaluation of the competitive protein binding assay for methotrexate binding to dihydrofolate reductaseJ C Drake, C J Allegra, B A Chabner
The Oncologist|July 26, 2017
The Harm in KratomJoshua Z Drago, Bennett Lane, Jonathan Kochav, et al.
Targeted Oncology|November 9, 2017
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest DevelopmentsAiko Nagayama, Leif W Ellisen, Bruce Chabner, et al.
The Oncologist|December 1, 2010
New trends and novel treatment for hepatocellular carcinoma: a global perspectiveAndrew X Zhu, Bruce A Chabner, Kenneth K Tanabe
Advances in Enzyme Regulation|January 1, 1989
Future directions for antifolate drug developmentC B Knight, P C Elwood, B A Chabner
The New England Journal of Medicine|March 1, 2013
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Pageof 46